LT3687567T - Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką - Google Patents
Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktikąInfo
- Publication number
- LT3687567T LT3687567T LTEPPCT/EP2018/075987T LTEP2018075987T LT3687567T LT 3687567 T LT3687567 T LT 3687567T LT EP2018075987 T LTEP2018075987 T LT EP2018075987T LT 3687567 T LT3687567 T LT 3687567T
- Authority
- LT
- Lithuania
- Prior art keywords
- adrenomedulin
- prophylaxis
- therapy
- binder
- disease symptoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192999 | 2017-09-25 | ||
| EP17203370 | 2017-11-23 | ||
| PCT/EP2018/075987 WO2019057992A2 (en) | 2017-09-25 | 2018-09-25 | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3687567T true LT3687567T (lt) | 2025-02-10 |
Family
ID=63722372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2018/075987T LT3687567T (lt) | 2017-09-25 | 2018-09-25 | Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220227854A1 (enExample) |
| EP (5) | EP3854414A1 (enExample) |
| JP (1) | JP7461875B2 (enExample) |
| KR (2) | KR20250004928A (enExample) |
| CN (2) | CN119215164A (enExample) |
| AU (2) | AU2018335438B2 (enExample) |
| BR (1) | BR112020005450A2 (enExample) |
| CA (1) | CA3076691A1 (enExample) |
| DK (1) | DK3687567T3 (enExample) |
| ES (1) | ES3001197T3 (enExample) |
| FI (1) | FI3687567T3 (enExample) |
| HR (1) | HRP20241795T1 (enExample) |
| HU (1) | HUE069945T2 (enExample) |
| IL (1) | IL273533A (enExample) |
| LT (1) | LT3687567T (enExample) |
| MX (1) | MX2020003538A (enExample) |
| MY (1) | MY204700A (enExample) |
| PL (1) | PL3687567T3 (enExample) |
| RS (1) | RS66415B1 (enExample) |
| SG (1) | SG11202002258WA (enExample) |
| SI (1) | SI3687567T1 (enExample) |
| WO (1) | WO2019057992A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022546061A (ja) | 2019-08-30 | 2022-11-02 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ショック症治療のための治療法の誘導および／または治療法の監視 |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| US20230104578A1 (en) * | 2020-02-27 | 2023-04-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| JP2023518380A (ja) * | 2020-03-16 | 2023-05-01 | アドレノメト アクチェンゲゼルシャフト | コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療 |
| CN111893085A (zh) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心（有限合伙） | 一种通过干细胞体外分化获得人工皮肤的方法及其应用 |
| KR20250040987A (ko) * | 2022-07-20 | 2025-03-25 | 상하이 제유 파마슈티칼 컴퍼니 리미티드 | 항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용 |
| WO2025152915A1 (zh) * | 2024-01-16 | 2025-07-24 | 上海济煜医药科技有限公司 | 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| BR0212256A (pt) | 2001-08-30 | 2004-08-31 | Biorexis Pharmaceutical Corp | Proteìnas de fusão de transferrina modificadas |
| DK2311432T3 (en) | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2006032436A2 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Use of microproteins as tryptase inhibitors |
| ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
| MX359570B (es) | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| BR112012004314A2 (pt) | 2009-08-27 | 2016-11-29 | Covagen Ag | compostos de ligação a il-17 e usos medicinais desses compostos |
| SI2506871T1 (sl) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| KR101436222B1 (ko) | 2009-12-14 | 2014-09-01 | 쉴 프로테인즈 게엠베하 | 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법 |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| PT3553084T (pt) * | 2011-11-16 | 2023-02-17 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda |
| SG11201402358RA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| IL283215B2 (en) * | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| EP2780717B1 (en) * | 2011-11-16 | 2016-12-21 | sphingotec GmbH | Adrenomedullin assays and methods for determining mature adrenomedullin |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| CN108362885B (zh) | 2013-03-20 | 2021-05-14 | 斯弗因高泰克有限公司 | 用于指导血压下降疗法的肾上腺髓质素 |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| JP7727371B2 (ja) * | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
-
2018
- 2018-09-25 CA CA3076691A patent/CA3076691A1/en active Pending
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/en not_active Withdrawn
- 2018-09-25 EP EP18781997.4A patent/EP3687567B1/en active Active
- 2018-09-25 SI SI201831189T patent/SI3687567T1/sl unknown
- 2018-09-25 CN CN202411206189.XA patent/CN119215164A/zh active Pending
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/ja active Active
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/en active Pending
- 2018-09-25 ES ES18781997T patent/ES3001197T3/es active Active
- 2018-09-25 CN CN201880062062.1A patent/CN111511390B/zh active Active
- 2018-09-25 PL PL18781997.4T patent/PL3687567T3/pl unknown
- 2018-09-25 KR KR1020247040657A patent/KR20250004928A/ko active Pending
- 2018-09-25 LT LTEPPCT/EP2018/075987T patent/LT3687567T/lt unknown
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/pt unknown
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/ko not_active Ceased
- 2018-09-25 HR HRP20241795TT patent/HRP20241795T1/hr unknown
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/en not_active Ceased
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
- 2018-09-25 FI FIEP18781997.4T patent/FI3687567T3/fi active
- 2018-09-25 MY MYPI2020001569A patent/MY204700A/en unknown
- 2018-09-25 RS RS20241461A patent/RS66415B1/sr unknown
- 2018-09-25 DK DK18781997.4T patent/DK3687567T3/da active
- 2018-09-25 EP EP24205659.6A patent/EP4488295A3/en active Pending
- 2018-09-25 HU HUE18781997A patent/HUE069945T2/hu unknown
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/en active Pending
- 2018-09-25 AU AU2018335438A patent/AU2018335438B2/en active Active
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/es unknown
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3720418T3 (da) | Nikotintablet | |
| HUE064141T2 (hu) | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére | |
| IL256175A (en) | Using exosomes to treat the disease | |
| LT2945642T (lt) | Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai | |
| IL256166B (en) | Compounds for use in treating neuromuscular disorders | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| PL3978074T3 (pl) | Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1 | |
| LT3592355T (lt) | Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| PL3600415T3 (pl) | Przeciwciało przeciwko receptorowi aktywiny typu II do stosowania w leczeniu niewydolności serca | |
| LT3113778T (lt) | Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| LT3153511T (lt) | 2-acilaminotiazolo dariniai, skirti panaudoti šlapimo pūslės/šlapimo takų ligų prevencijai arba gydymui | |
| GB201721287D0 (en) | Treatment for inflammatory disease | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| CY2024037I1 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| PT3630164T (pt) | Dulaglutida para o tratamento de doença renal crónica | |
| IT201600105430U1 (it) | Letto ribaltabile per persone con disabilità | |
| LT3554501T (lt) | Deksmedetomidinas arba medetomidinas, skirti naudoti gydant naminių gyvūnų atsiskyrimo nerimą | |
| IL258610B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| IL270788A (en) | Sulfonylurea compounds in the treatment of disease associated with uv-induced damage | |
| LT3337494T (lt) | Lizobaktinas, skirtas naudoti galvijų mastitui gydyti |